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ABSTRACT	
	 2
The	isolation	and	structural	characterization	of	three	new	heterocyclic	and	macrocyclic	
peptides,	balgacyclamides	A–C	from	Microcystis	aeruginosa	EAWAG	251	is	reported.	The	
constitution	was	determined	by	2D‐NMR	methods	and	mass	spectrometry	and	the	configuration	
was	assigned	by	HPLC‐MS	methods	using	Marfey's	method	as	well	as	GC‐MS	using	authentic	
standards.	Balgacyclamides	A	and	B	were	active	against	Plasmodium	falciparum	K1	in	the	low	
micromolar	range,	while	displaying	low	toxicity	to	rat	myoblasts.	
	
INTRODUCTION	
	 Cyclic	peptides	and	derived	macrocycles	have	recently	received	significant	interest	in	a	
variety	of	fields,	ranging	from	biosynthesis	studies	to	drug	discovery	and	development1,	The	
potentially	large,	but	structurally	often	well	defined	conformational	space	sampled,	combined	
with	the	variety	of	amino	acids	renders	peptides	ideally	suited	to	interact	with	many	receptors	
or	to	interfere	with	protein/protein	interactions.1	Cyanobactins	constitute	a	particular	subset	of	
cyclic	peptides	produced	by	cyanobacteria	and	can	be	defined	as	cyclic,	ribosomally	produced	
peptides	(RiPP)2	containing	heterocyclic	modifications.3	They	have	been	found	not	only	in	the	
producing	organism,	but	also	in	other	animals	where	they	have	been	suggested	to	be	of	
symbiotic	or	dietary	origin.4	A	particular	subset,	the	cyclamides	are	structurally	well	defined	
macrocyclic	hexapeptides,	where	often	hydrophobic	residues	flanked	by	heterocyclic	rings	such	
as	oxazol(ine)	or	thiazol(ine)	residues	are	observed.5	While	their	biosynthesis	has	been	
investigated,2‐4,5m	the	bioactivity	of	these	compounds	both	in	their	ecological	niche	as	well	as	in	a	
therapeutic	setting	has	received	much	less	attention.	Early	assumptions	on	the	bioactivity	
suggested	a	role	as	allelochemicals,	which	has	been	supported	by	algicidal	effects.6	Another	
seemingly	unrelated	activity	is	related	to	multidrug‐resistance	reversing	activity,	which	has	
been	reported	for	several	members	of	this	family.7	Most	interestingly,	Gerwick	and	coworkers	
reported	significant	antimalarial	activity	for	the	venturamides.8	Independently,	we	have	
determined	antimalarial	activity	for	the	aerucyclamides9	that	displayed	improved	activity	when	
compared	to	the	earlier	study.8	The	best	compound	in	this	series,	aerucyclamide	B	displayed	
antimalarial	IC50	of	0.7	μM	against	the	Plasmodium	falciparum	K1	strain	with	a	high	selectivity	
over	the	L6	rat	myoblasts	cell	line.	Aerucyclamide	B	was	taken	up	as	a	lead	structure	for	a	
medicinal	chemistry	follow	up	program	by	Serra	and	coworkers	that	build	on	the	first	successful	
total	synthesis	of	this	compound.10	Whereas	these	authors	were	able	to	briefly	delineate	a	first	
structure	activity	relationship	study,	currently,	the	role	of	the	different	units	on	activity	
remained	unclear.	The	current	main	hypothesis	suggests	that	the	degree	of	unsaturation	of	the	
heterocyclic	rings	is	correlated	with	biological	activitiy,8–10	with	higher	unsaturation	leading	to	
more	potent	compounds.	While	this	hypothesis	is	supported	by	several	compounds	(e.g.	
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oxidation	of	an	thiazoline	to	an	thiazole	in	aerucyclamide	A	and	B	led	to	10	times	increased	
activity),	more	compounds	are	needed	to	corroborate	these	observations.	In	this	study,	we	
report	on	the	isolation	of	new	cyclamides	from	cyanobacteria,	and	evaluate	the	antimalarial	
properties	in	the	P.	falciparum	K1	assay. 
RESULTS	AND	DISCUSSION	
The	balgacyclamide	were	isolated	from	aqueous	methanolic	extracts	of	Microcystis	aeruguinosa	
EAWAG	251	(identical	to	PCC	7820).	These	compounds	were	purified	by	a	combination	of	C18‐
SPE,	semi‐preparative	and	analytical	reverse	phase	HPLC	methods.	The	structure	determination	
proved	to	be	challenging	due	to	the	low	isolation	yield	of	0.37	mg,	0.10	mg,	and	0.53	mg	per	10	
liters	of	culture,	for	the	balgacyclamides	A	(1),	B	(2)	and	C	(3)	respectively.	
Balgacyclamide	A	(1)	displayed	an	exact	mass	of	m/z	533.2552,	which	supports	the	molecular	
formula	C25H37N6O5S	(calcd	533.2546)	for	the	[M+H]+	pseudomolecular	ion.	The	1H	spectrum	
(DMSO‐d6,	500MHz)	displayed	the	typical	pattern	of	a	peptide	(NMR	data	in	table	1).	Three	NH	
resonances	were	present	as	doublet.	Based	on	characteristic	signals	and	COSY	correlations,	the	
fragments	NH‐Ala,	NH‐Val	and	NH‐Ile	were	assigned.	HSQC	and	HMBC	experiments	were	used	to	
assign	the	13C	chemical	shifts.	Furthermore,	two	Thr	residues	missing	the	NH	resonance	were	
assigned	as	methyloxazoline	(MeOzn)	moieties.	The	last	fragment	was	assigned	as	a	thiazole	
(Tzl)	based	on	its	characteristic	signals	(H‐18	Tzl,	singlet,	∂H	8.30	ppm,	C‐18	Tzl	∂C	126.4	ppm).11	
The	sequence	of	the	amino	acids	was	challenging	to	determine	because	of	the	presence	of	
resonance	overlap	in	the	1H	and	13C	spectra.	HMBC	long‐range	correlations	were	measured	in	
two	different	solvents,	DMSO‐d6	and	CDCl3,	to	establish	the	sequence	(NMR	data	in	CDCl3	are	
available	in	the	supporting	information).	From	the	HMBC	spectrum	in	DMSO‐d6,	correlations	
from	H‐2	of	MeOzn1	to	C‐5	of	Val	and	from	NH‐6	of	Ile	to	C‐1	of	MeOzn1	were	unambiguous.	
Additionaly,	a	long	range	J	coupling	of	2.0	Hz	was	observed	between	the	two	C()‐H	of	the	
MeOzn1	and	of	the	Val	residue.	These	long	range	J	couplings	are	frequently	found	in	cyclamides	
with	oxazoline	ring	system.9,12	From	the	HMBC	spectrum	recorded	in	CDCl3,	correlation	from	
NH‐2	of	Val	to	C‐9	of	MeOzn2		and	from	H‐18	of	Tzl	to	C‐19	of	Ile	allowed	to	establish	the	partial	
sequence	‐Tzl‐Ile‐MeOzn1‐Val‐MeOzn2‐	(figure	1).	Only	the	position	of	Ala	was	not	established	
with	the	NMR	data.	Based	on	the	molecular	formula,	balgacyclamide	A	(1)	required	to	be	
teracyclic,	therefore	the	peptide	has	to	be	a	macrocycle.	Therefore,	the	sequence	of	the	peptide	
was	assigned	as	cyclo‐(‐MeOzn1‐Val‐MeOzn2‐Ala‐Tzl‐Ile‐)‐.	
Balgacyclamide	B	(2)	displayed	an	exact	mass	of	m/z	551.2657,	which	supports	the	molecular	
formula	C25H39N6O6S	(calcd	551.2652)	for	the	[M+H]+	pseudomolecular	ion.	Its	molecular	
formula	suggests	that	2	is	a	H2O	adduct	of	balgacyclamide	A	(1).	The	constitution	of	2	was	
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obtained	utilizing	the	same	methods	as	for	balgycyclamide	A	(1).	As	for	1,	NH‐Ala,	NH‐Val	and	
NH‐Ile	were	identified,	but	instead	of	two	MeOzn	in	1,	one	MeOzn	and	one	NH‐Thr	were	
presents	accounting	for	the	difference	in	the	molecular	formula.	The	sequence	was	established	
by	HMBC	long‐range	correlations	(figure	1).	Correlations	were	observed	from	H‐2	of	MeOzn	to	
C‐5	of	Val,	from	H‐6	of	Val	to	C‐9	of	Thr,	from	H‐10	of	Thr	to	C‐13	of	Ala,	from	H‐14	of	Ala	to	C‐16	
of	Tzl,	from	H‐18	of	Tzl	to	C‐19	of	Ile	and	from	H‐20	of	Ile	to	C‐1	of	MeOzn.	As	the	13C	chemical	
shift	of	two	carbonyls	and	the	thioimidate	(why	thioamidate	if	it	is	MeOzzn???)	were	close	from	
each	other	(C‐1	MeOzn	∂C	169.7,	C‐9	Thr	∂C	169.4	and	C‐19	Ile	∂C	169.6),	the	sequence	was	
confirmed	with	ROESY	correlations.	Correlations	were	observed	between	H‐4	of	MeOzn	and	H‐6	
of	Val,	between	NH‐2	of	Val	and	H‐10	and	H‐11	of	Thr,	between	NH‐3	of	Thr	and	H‐14	and	H‐15	
of	Ala	and	between	NH‐6	of	Ile	and	H‐2	of	MeOzn.	As	for	cyclamide	1,	a	long	range	J	coupling	of	
1.6	Hz	was	observed	between	the	two	C()‐H	of	the	MeOzn	and	of	the	Val	residue.	Only	one	link	
between	C‐16	and	C‐17	of	Tzl	could	not	be	established	with	the	different	NMR	experiments.	
Again,	according	to	the	molecular	formula,	balgacyclamide	B	(2)	was	required	to	be	tricyclic	and	
therefore	C‐16	and	C‐17	needed	to	be	connected,	thus	closing	the	macrocyclic	ring	of	cyclo‐(‐
MeOzn‐Val‐Thr‐Ala‐Tzl‐Ile‐)‐.	
Balgacyclamide	C	(3)	displayed	an	exact	mass	of	m/z	585.2512,	which	supports	the	molecular	
formula	C28H37N6O6S	(calcd	585.2495)	for	the	[M+H]+	pseudomolecular	ion.	The	six	fragments	
MeOzn,	NH‐Phe,	NH‐Thr,	NH‐Gly,	Tzl	and	NH‐Ile	were	identified	as	described	above.	HMBC	
spectroscopy	allowed	the	establishment	of	the	sequence	through	a	series	of	long‐range	
correlations:	from	H‐2	of	MeOzn	to	C‐5	of	Phe,	from	H‐6	of	Phe	to	C‐12	of	Thr,	from	NH‐3	of	Thr	
to	C‐16	of	Gly,	from	H‐17	of	Gly	to	C‐18	of	Tzl,	from	H‐20	of	Tzl	to	C‐21	of	Ile	and	from	NH‐6	of	
Ile	to	C‐1	of	MeOzn,	which	established	the	sequence	as	cyclo‐(‐MeOzn‐Phe‐Thr‐Gly‐Tzl‐Ile‐)‐.	
The	configuration	of	the	balgacyclamides	A‐C	(1‐3)	was	determined	with	the	same	strategy	
as	for	the	aerucyclamides.9	First,	the	compounds	were	ozonized	to	avoid	the	epimerization	of	
the	Ile	residues	that	are	next	to	the	thiazole	residues,	as	it	is	known	that	amino	acids	next	to	
thiazole	or	oxazole	residues	are	prone	to	epimerization	during	hydrolysis.13	The	compounds	
were	then	hydrolyzed,	and	half	the	amount	of	the	hydrolyzed	compounds	was	derivatized	with	
the	Marfey’s	reagent14	while	the	other	half	was	derivatized	with	trifluoroacetic	acid	anhydride.	
The	Marfey’s	derivatives	were	analyzed	by	HPLC‐MS	to	establishe	the	configuration	of	the	Ala,	
Thr,	Val	and	Phe	amino	acids	by	comparing	the	retention	time	with	authentic	derivatized	amino	
acids	as	standards	and	co‐injection	of	authentic	and	natural	samples	was	realized	when	
necessary.	The	TFA	derivatives	were	analyzed	by	GC‐MS	to	establish	the	configuration	of	the	Ile	
amino	acids.	It	was	necessary	to	perform	a	co‐injection	analysis	with	standard	derived	Ile	to	
differentiate	between	the	D‐Ile	and	D‐allo‐Ile.	This	methodology	established	the	presence	of	D‐
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Ala,	L‐Thr,	L‐Val	and	D‐allo‐Ile	for	the	balgacyclamides	A	and	B	(1	and	2)	and	L‐Thr,	L‐Phe,	D‐
allo‐Ile	for	balgacyclamide	C	(3).	These	experiments	therefore	established	the	structures	of	the	
balgacyclamides	A‐C	as	shown	for	compounds	1‐3	(Figure	1)		
The	balgacyclamides	A	(1)	and	B	(2)	were	evaluated	for	their	antiparasite	activity.	Compounds	1	
and	2	displayed	micromolar	IC50	activity	(9.0	and	8.2	µM	respectively)	against	the	chloroquine‐
resistant	strain	K1	of	P.	falciparum,	whereas	1	and	2	are	showed	only	some	moderate	activity	
against	other	parasites,	IC50	=	59	and	51	µM	respectively	against	Trypanosoma	brucei	rhodesiense	
STIB	900	and	IC50	=	28	µM	for	2	against	Leishmania	donovani	MHOM‐ET‐67/L82.	The	
balgacyclamides	A	and	B	also	displayed	selectivity	in	respect	to	their	cytotoxicity	to	the	L6	rat	
myoblast	cell	line,	for	which	no	activity	was	detected	up	to	150	µM.	These	results	are	in	
agreement	with	previous	antiparasite	evaluations	of	cyclamide	compounds.	The	venturamides	A	
and	B	display	IC50	of	8.2	and	5.2	µM	against	P.	falciparum8,	while	the	aerucyclamides	A,	B,	C	and	
D	display	IC50	of	5.0,	0.7,	2.3	and	6.3	µM	respectively.9	It	is	interesting	to	note	that	opening	of	the	
oxazoline	ring	in	1	did	not	result	in		significant	lower	bioactivity.		
In	conclusion,	we	have	reported	the	isolation	and	structure	determination	of	the	
balgacyclamides	A	(1),	B	(2)	and	C	(3)	from	Microcystis	aeruguinosa	EAWAG	251.	
Balgacyclamides	A	(1)	and	B	(2)	were	evaluated	for	their	antiparasite	activity	and	displayed	
micromolar	IC50	activity	against	P.	falciparum	with	a	good	selectivity	compared	to	their	
cytotoxicity.	
	
EXPERIMENTAL	SECTION	
General	Experimental	Procedures.	NMR	spectra	were	acquired	on	a	Bruker	Avance	500,	a	
Bruker	DRX‐600	and	a	Bruker	Avance	II	800,	all	equipped	with	cryoprobes.	The	spectra	were	
referred	to	residual	solvent	proton	and	carbon	signals	(δH	2.50,	δC	39.5	for	DMSO‐	d6	and	δH	7.26,	
δC	77.2	for	CDCl3).	Accurate	mass	ESI	spectra	were	recorded	on	a	Micromass	(ESI)	Q‐TOF	Ultima	
API.	HPLC	purification	and	analyses	were	performed	on	a	Dionex	HPLC	system	equipped	with	a	
P680	pump,	an	ASI‐100	automated	sample	injector,	a	TCC‐100	thermostated	column	
compartment,	a	PDA‐100	photodiode	array	detector,	a	Foxy	Jr.	fraction	collector,	and	a	MSQ‐ESI	
mass	spectrometric	detector.	The	determination	of	the	Ile	enantiomers	was	carried	out	on	a	GC‐
FID	instrument	(Thermo	Focus	with	a	Thermo	AS	3000	autosampler).	
Sources	and	Cultivation	of	Cyanobacteria.	M.	aeruginosa	EAWAG	251	was	obtained	from	the	
Eawag	(Swiss	Federal	Institute	of	Aquatic	Science	and	Technology)	Culture	Collection	of	
Cyanobacteria,	currently	at	the	University	of	Basel.	This	strain	is	identical	as	the	M.	aeruginosa	
PCC7820	from	the	Pasteur	Culture	Collection	of	Cyanobacteria,	Paris,	France.	The	strain	was	
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grown	in	a	20	L	batch	reactor	(Zehnder	medium15	)	with	continuous	aeration	and	a	light/dark	
cycle	of	12:12	h.	The	biomass	was	isolated	by	centrifugation	and	subsequently	kept	frozen	until	
extraction.	
Extraction	and	Isolation.	The	biomass	was	extracted	first	with	100%	MeOH	and	then	twice	
with	60%	MeOH.	The	extract	was	separated	from	the	biomass	by	centrifugation.	MeOH	was	
removed	from	the	combined	extracts	by	evaporation	under	reduced	pressure	and	the	mixture	
was	then	dried	by	lyophilization.	The	resulting	powder	was	dissolved	in	80%	MeOH	and	
centrifuged	to	remove	remaining	particles.	The	solutions	were	then	sequentially	loaded	to	a	C18	
SPE	column	(Supelco	Discovery	DSC‐18,	10	g,	conditioned	with	10%	aqueous	MeOH),	and	eluted	
with	30%,	60%,	80%,	and	100%	aqueous	MeOH	solutions.	MeOH	was	removed	from	the	
combined	extract	by	evaporation	under	reduced	pressure	and	and	the	mixture	was	then	dried	
by	lyophilization.	The	resulting	oil	from	the	80%	MeOH	fraction	was	redissolved	in	80%	MeOH,	
and	the	compounds	were	isolated	using	multiple	C18	RP‐HPLC	runs	(Phenomenex	Gemini	C18	5	
μm;	150	×	10	mm).	The	gradient	MeOH/H2O	at	a	flow	of	5	mL/min	was	35%	MeOH	to	100%	
over	30	min.	The	column	was	then	washed	for	10	min	with	100%	MeOH	and	stabilized	for	the	
next	cycle	in	10	min	with	35%	MeOH.	MeOH	was	removed	under	reduced	pressure	and	the	
compounds	were	then	dried	with	a	stream	of	N2.	Balgacyclamides	A,	B	and	C	eluted	at	17.4,	13.2	
and	14.3	min	respectively.	Balgacyclamide	B	and	C	were	further	purified	by	HPLC	using	multiple	
runs	on	an	analytical	column	C18	RP‐HPLC	(Phenomenex	Gemini	C18	5	μm;	150	×	4.6	mm).	The	
gradient	CH3CN/H2O	at	a	flow	of	1	mL/min	was	30%	CH3CN	to	100%	over	60	min.	The	column	
was	then	washed	for	10	min	with	100%	CH3CN	and	stabilized	for	the	next	cycle	in	10	min	with	
30%	CH3CN.	Balgacyclamide	B	and	C	eluted	at	10.0	and	11.2	min	respectively.	The	compounds	
were	dried	as	described	above.	The	isolation	yields	of	the	balgacyclamides	A	(1),	B	(2)	and	C	(3)	
were	0.55	mg,	0.15	mg	and	0.80	mg	per	15	liters	of	culture,	respectively.	
	
Balgacyclamide	A	(1):	colorless,	amorphous	solid;	UV	(CH3CN/	water,	55.5/45.5)	λmax	234	nm;	
1H	and	13C	NMR	data	(DMSO‐d6),	see	Table	1;	1H	and	13C	NMR	data	(CDCl3),	see	supp.	info.;	
HRESI‐QqTof‐MS	m/z	[M	+	H]+	533.2552	(calcd	for	C25H37N6O5S,	533.2546).	
	
Balgacyclamide	B	(2):	colorless,	amorphous	solid;	UV	(CH3CN/	water,	42/58)	λmax	236	nm;	1H	
and	13C	NMR	data	(DMSO‐d6),	see	Table	2;	HRESI‐QqTof‐MS	m/z	[M	+	H]+	551.2657	(calcd	for	
C25H39N6O6S,	551.2652).	
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Balgacyclamide	C	(3):	colorless,	amorphous	solid;	UV	(CH3CN/	water,	43/57)	λmax	239	nm;	1H	
and	13C	NMR	data	(DMSO‐d6),	see	Table	3;	HRESI‐QqTof‐MS	m/z	[M	+	H]+	585.2512	(calcd	for	
C28H37N6O6S,	585.2495).	
	
Ozonolysis	of	compounds	1–3	:	Each	compound	(0.1	mg,	0.2	μmol)	was	dissolved	in	0.3	mL	of	
dry	CH2Cl2,	ozonized	at	room	temperature	for	5	min	and	the	solvent	was	removed	under	a	
stream	of	N2.	
Hydrolysis	of	compounds	1–3:	Each	ozonized	compound	was	hydrolyzed	in	a	closed	
microwave	tube	by	adding	0.5	mL	of	freshly	prepared	6	N	HCl	at	108°C	for	20	h.	The	solvent	was	
concentrated	by	a	stream	of	N2	and	removed	by	lyophilization	and	then	the	residue	was	
dissolved	in	0.06	mL	of	H2O.	
Marfey’s	Analysis	of	compounds	1–3:	Half	of	the	solution	of	the	hydrolysed	compounds	was	
treated	with	0.03	mL	of	a	1%	N‐(2,4‐dinitro‐5‐fluorophenyl)‐L‐alaninamide	(FDAA)	solution	in	
acetone	and	0.03	mL	of	6%	Et3N	in	H2O	at	50°C	for	1	h	in	a	closed	HPLC	vial.	The	reaction	was	
quenched	with	0.03	mL	of	5%	acetic	acid	and	the	solvent	was	removed	by	lyophilisation.	The	
residue	was	solved	in	0.03	mL	of	MeOH	and	analyzed	by	RP‐HPLC	using	an	Agilent	Zorbax	SB‐
C18	(3.55	μm	150	x	2.1	mm).	The	mobile	phases	were	A,	5%	acetic	acid	in	H2O,	and	B,	
MeCN/MeOH	(9:1).	The	column	was	stabilized	for	20	min	with	5%	of	B,	then	the	gradient	went	
from	5‐50%	in	50	min	and	the	column	was	washed	with	100%	of	B	for	20	min.	The	flow	was	set	
at	0.25	mL/min	and	the	temperature	of	the	column	oven	at	50°C.		
By	comparison	of	the	retention	times	of	the	derivatized	commercially	available	amino	acids	the	
configuration	can	be	determined	except	for	isoleucine.	The	retention	times	(min)	for	the	
derivatized	standard	amino	acids	were:	L‐Ala	28.25;	D‐Ala	32.21;	L‐Val	35.89;	D‐Val	40.64;	L‐Phe	
41.01;	D‐Phe	46.39;	L‐Thr	21.09;	L‐allo‐Thr	22.22;	D‐allo‐Thr	24.73;	D‐Thr	28.89;	L‐Ile	40.47;	L‐
allo‐Ile	40.45;	D‐Ile	47.38	and	D‐allo‐Ile	47.46.	
TFA	Derivatives	and	Chiral	GC	Analysis	of	1,	2	and	3	:	0.03	mL	of	the	hydrolyzed	compound	
solution	was	transferred	to	a	GC	vial	and	the	solvent	was	evaporated.	The	residue	was	treated	
with	0.03	mL	of	trifluoroacetic	acid	anhydride	at	room	temperature	for	12	hours	and	quenched	
with	0.03	mL	of	MeOH.	The	configuration	of	isoleucine	was	determined	after	analyses	on	a	chiral	
GC	column	(Permabond‐L‐Chirasil‐Val;	25	m,	0.25	mm,	Marcherey‐Nagel,	Düren,	Germany)	with	
the	following	conditions:	2	min	at	80°C,	80	to	180°C	at	rate	of	8°C	min‐1	and	10	min	at	180°C	
with	a	split	ratio	10:1,	at	a	flow	of	1mL/min	and	a	FID	detector	at	250°C.	
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The	four	commercially	available	stereoisomers	of	isoleucine	were	derivatized	with	the	same	
method	as	presented	above	and	the	retention	times	(min)	were:	D‐allo‐Ile	6.20,	L‐allo‐Ile	6.35,	D‐
Ile	6.39	and	L‐Ile	6.45.	
Configuration	of	compounds	1–3	:	
Balgacyclamide	A	(1)	:	from	ozonolysis−hydrolysis−Marfey	D‐Ala,	L‐Thr	(confirmed	by	a	co‐
injection	with	L‐allo‐Thr),	L‐Val	and	D‐Ile	or	D‐allo‐Ile	and	from	ozonolysis−hydrolysis−TFA	D‐
allo‐Ile	(confirmed	by	a	co‐injection	with	D‐Ile).	
Balgacyclamide	B	(2)	:	from	ozonolysis−hydrolysis−Marfey	D‐Ala,	L‐Thr,	L‐Val	and	D‐Ile	or	D‐
allo‐Ile	and	from	ozonolysis−hydrolysis−TFA	D‐allo‐Ile	(confirmed	by	a	co‐injection	with	D‐Ile).	
Balgacyclamide	C	(3)	:	from	ozonolysis−hydrolysis−Marfey	L‐Thr,	L‐Phe	and	D‐Ile	or	D‐allo‐Ile	
and	from	ozonolysis−hydrolysis−TFA	D‐allo‐Ile	(confirmed	by	a	co‐injection	with	D‐Ile).	
	
Plasmodium	falciparum,	Trypanosoma	b.	rhodesiense	and	Cytotoxicity	in	Vitro	Assay	were	
performed	according	to	procedures	previously	described.9b	
	 9
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Table	1:	NMR	spectroscopic	data	(500MHz,	DMSO‐d6)	for	balgacyclamide	A	(1).	
balgacyclamide	A	
C/N	no.	 C	 H	(J	in	Hz)	 HMBC	a	
1	 168.9,	qC	 	 	
2	 72.4,	CH	 4.41,	dd	(6.8,	2.0)	 1,	4,	5	
3	 79.3,	CH	 4.95,	dq	(6.5,	6.4)	 1,	5	
4	 20.4,	CH3	 1.37,	d	(6.4)	 2,	3	
5	 166.0,	qC	 	 	
6	 50.6,	CH	 4.48,	ddd	(9.0,	2.5,	2.0)	 5,	7,	8’	
7	 30.8,	CH	 1.98,	m	 	
8	 18.1,	CH3	 0.62,	d	(6.9)	 6,	7,	8’	
8’	 15.1,	CH3	 0.35,	d	(6.9)	 6,	7,	8	
NH	(2)	 	 7.35,	d	(9.0)	 5,	9	
9	 169.7,	qC	 	 	
10	 72.7,	CH	 4.33,	d	(6.7)	 9	or	13,	11,	12	
11	 81.1,	CH	 4.79,	dq	(6.7,	6.3)	 9	or	13	
12	 21.0,	CH3	 1.43,	d	(6.3)	 9	or	13,	10,	11	
13	 169.7,	qC	 	 	
14	 42.6,	CH	 4.73,	dq	(7.7,	6.9)	 13,	15,	16	
15	 19.3,	CH3	 1.47,	d	(6.9)	 14	
NH	(4)	 	 8.30,	d	(7.7)	 	
16	 159.1,	qC	 	 	
17	 148.0,	qC	 	 	
18	 124.6,	CH	 8.30,	s	 17,	19	
19	 169.7,	qC	 	 	
20	 54.0,	CH	 5.23,	dd	(8.4,	5.7)	 19,	21,	22	
21	 40.4,	CH	 1.92,	m	 	
22	 14.2,	CH3	 0.93,	d	(6.8)	 20,	21,	23	
23a	
23b	
25.1,	CH2	 1.44,	m	
1.04,	m	
	
21	
24	 11.1,	CH3	 0.88,	dd	(7.4,	7.4)	 21,	23	
NH	(6)	 	 8.21,	d	(8.4)	 1	
a	HMBC	correlations	are	given	from	proton(s)	stated	to	the	indicated	carbon	atom.	 	
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Table	2	:	NMR	spectroscopic	data	(500MHz,	DMSO‐d6)	for	balgacyclamide	B	(2).	
balgacyclamide	B	
C/H	no.	 C	 H	(J	in	Hz)	 HMBC	a	 ROESY	
1	 169.7,	qC	 	 	 	
2	 73.4,	CH	 4.34,	dd	(6.2,	1.6)	 1,	4,	5	 4	
3	 78.0,	CH	 4.84,	dq	(6.2,	6.2)	 1,	2,	5	 	
4	 20.0,	CH3	 1.29,	d	(6.2)		 2,	3	 	
5	 165.7,	qC	 	 	 	
6	 51.1,	CH	 4.43,	ddd	(8.6,	3.7,	1.6)	 5,	7,	8,	8’,	9	 4,	8,	8’	
7	 30.3,	CH	 1.95,	m	 5,	6,	8,	8’	 8,	8’	
8	 17.8,	CH3	 0.67,	d	(6.9)	 6,	7,	8’	 	
8’	 15.8,	CH3	 0.53,	d	(6.9)	 6,	7,	8	 	
NH	(2)	 	 6.95,	d	(8.6)	 5,	6,	9	 6,	7,	8,	8’,	10,	11	
9	 169.4,	qC	 	 	 	
10	 58.5,	CH	 4.23,	dd	(8.7,	3.5)	 9,	11,	13	 12	
11	 65.0,	CH	 4.19,	m	 12	 12	
12	 20.0,	CH3	 1.07,	d	(6.3)	 10,	11	 	
OH	 	 4.76,	d	(5.6)	 10,	11,	12	 12	
NH	(3)	 	 8.47,	d	(8.7)	 10,	11,	13	 10,	11,	12,	14,	15,	OH,	
NH(2)	
13	 172.4,	qC	 	 	 	
14	 47.8,	CH	 4.80,	m	 13,	15,	16	 	
15	 17.4,	CH3	 1.30,	d	(6.5)	 13,	14	 	
NH	(4)	 	 8.22,	d	(7.9)	 13,	14,	16	 14,	15,	NH(2)	
16	 159.6,	qC	 	 	 	
17	 147.9,	qC	 	 	 	
18	 123.6,	CH	 8.22,	s	 17,	19	 	
19	 169.6,	qC	 	 	 	
20	 54.4,	CH	 5.13,	dd	(8.5,	5.5)	 1,	19,	21,	22,	23	 22,	23b	
21	 39.5,	CH	 1.91,	m	 19,	20,	22,	23,	
24	
24	
22	 14.1,	CH3	 0.90,	d	(6.8)	 20,	21,	23	 	
23a	
23b	
25.2,	CH2	 1.44,	m	
1.11,	m	
20,	21,	22,	24	
20,	21,	22,	24	
	
24	 10.9,	CH3	 0.88,	dd	(7.3,	7.3)	 20,	21,	23	 	
NH	(6)	 	 8.43,	d	(8.5)	 1,	20	 2,	6,	20,	21,	23a,	24		
	 12
a	HMBC	correlations	are	given	from	proton(s)	stated	to	the	indicated	carbon	atom.	
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Table	3:	NMR	spectroscopic	data	(500MHz,	DMSO‐d6)	for	balgacyclamide	C	(3).	
balgacyclamide	C	
C/H	no.	 C	 H	(J	in	Hz)	 HMBC	a	 ROESY	
1	 169.0,	qC	 	 	 	
2	 73.8,	CH	 4.28,	dd	(7.6,	1.7)	 1,	3,	4,	5		 4	
3	 78.3,	CH	 4.88,	dq	(7.6,	6.4)	 1,	2,	5	 	
4	 20.3,	CH3	 1.36,	d	(6.4)	 2,	3	 	
5	 165.0,	qC	 	 	 	
6	 48.0,	CH	 4.76,	m	 5,	7,	8,	12	 7a	
7a	
7b	
36.7,	CH2	 2.98,	dd	(13.6,	5.2)	
2.86,	dd	(13.6,	6.0)	
5,	6,	8,	9/9’	
5,	6,	8,	9/9’	
	
8	 135.4,	qC	 	 	 	
9/9’	 129.0,	CH	 7.01,	d	(7.4)	 7,	9/9’,	11	 3,	6,	7b,	OH	
10/10’	 127.4,	CH	 6.94,	dd	(7.4,	7.4)	 8,	9/9’,	10/10’	 3,	6,	7b,	OH	
11	 126.0,	CH	 6.82,	t	(7.4)	 9/9’	 	
NH	(2)	 	 7.45,	d	(7.5)	 12	 9/9’,	6,	13,	14	
12	 169.2	qC	 	 	 	
13	 58.8,	CH	 4.19,	dd	(9.0,	4.5)	 12,	14,	15	 15	
14	 65.4,	CH	 4.09,	m	 12	 15	
15	 19.8,	CH3	 0.92,	d	(6.3)	 13,	14	 	
OH	 	 4.91,	d	(5.4)	 13,	14,	15	 14,	15	
NH	(3)	 	 7.81,	d	(9.0)	 13,	16	 9/9’,	13,	14,	15,	17a,	OH,	NH(2)	
16	 169.6,	qC	 	 	 	
17a	
17b	
42.9,	CH2	 4.39,	dd	(15.3,	7.5)	
3.63,	dd	(15.3,	3.3)	
16,	18	
16,	18	
	
NH	(4)	 	 8.26,	dd	(7.5,	3.3)	 	 17a,	17b,	NH(2),	NH(3),	NH(6)	
18	 159.9,	qC	 	 	 	
19	 147.5,	qC	 	 	 	
20	 123.7,	CH	 8.29,	s	 18,	19,	21	 	
21	 168.6,	qC	 	 	 	
22	 54.1,	CH	 5.18,	dd	(8.1,	5.2)	 21,	23,	24,	25	 23,	26	
23	 39.8,	CH	 1.92,	m	 	 26	
24	 13.9,	CH3	 0.84,	d	(6.9)	 22,	23,	25	 	
25a	
25b	
25.0,	CH2	 1.45,	m	
0.98,	m	
22,	23,	24,	26	
22,	23,	24	
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26	 11.2,	CH3	 0.87,	dd	(7.4,	7.4)	 23,	25	 	
NH	(6)	 	 7.98,	d	(8.2)	 1,	22	 2,	22,	23,	24,	25a	
a	HMBC	correlations	are	given	from	proton(s)	stated	to	the	indicated	carbon	atom.	
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Table	4.	Biological	evaluation	of	balgacyclamides	A	(1)	and	B	(2)	against	Plasmodium	falciparum	
K1,	Trypanosoma	brucei	rhodesiense	STIB	900,	Trypanosoma	cruzi	Tulahuen	C4,	Leishmania	
donovani	MHOM‐ET‐67/L82	and	rat	myoblast	cells	L6	(IC50	values	are	reported	µM	as	
concentrations).	
	 P.f.a	 T.	b.	rhod.b	 T.	cruzi	c	 L.	donovani	d	 L6e	
1	 9.0	 59	 >150	 >150	 >150	
2	 8.2	 51	 >150	 28	 >150	
a	Plasmodium	falciparum	K1	
b	Trypanosoma	brucei	rhodesiense	STIB	900	
c	Trypanosoma	cruzi	Tulahuen	C4	
d	Leishmania	donovani	MHOM‐ET‐67/L82	
e	Rat	myoblast	L6	cells	
	
	
Figure	1:	Key	COSY,	ROESY	and	HMBC	correlations	in	balagacyclamides	A	(1),	B	(2)	and	C	(3).	
Note	the	observed	long‐range	J	coupling	between	H‐2	and	H‐6	in	both	balgacyclamides	A	(1)	and	
B	(2).	
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